Immuneering (IMRX) Cash from Investing Activities (2020 - 2024)
Historic Cash from Investing Activities for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to $5.5 million.
- Immuneering's Cash from Investing Activities rose 7525.65% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $26.4 million, marking a year-over-year increase of 26229.68%. This contributed to the annual value of $26.4 million for FY2024, which is 26229.68% up from last year.
- As of Q4 2024, Immuneering's Cash from Investing Activities stood at $5.5 million, which was up 7525.65% from -$5.4 million recorded in Q3 2024.
- Over the past 5 years, Immuneering's Cash from Investing Activities peaked at $22.2 million during Q2 2022, and registered a low of -$52.8 million during Q3 2021.
- For the 5-year period, Immuneering's Cash from Investing Activities averaged around -$5398.8, with its median value being $1.6 million (2020).
- As far as peak fluctuations go, Immuneering's Cash from Investing Activities plummeted by 94174624.31% in 2021, and later skyrocketed by 11185296.61% in 2022.
- Over the past 5 years, Immuneering's Cash from Investing Activities (Quarter) stood at -$38058.0 in 2020, then plummeted by 59829.41% to -$22.8 million in 2021, then skyrocketed by 135.74% to $8.2 million in 2022, then crashed by 61.57% to $3.1 million in 2023, then surged by 75.26% to $5.5 million in 2024.
- Its Cash from Investing Activities was $5.5 million in Q4 2024, compared to -$5.4 million in Q3 2024 and $5.0 million in Q2 2024.